BSX · 10-Q · 2026Q3

BOSTON SCIENTIFIC CORP

Filed 2026-11-02 · Healthcare · View original filing on EDGAR

Ranked Events

• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Boston Scientific agreed to acquire 100% of Penumbra for approximately $14.5 billion, valued at $374 per share when announced on January 15, 2026. Penumbra stockholders approved the transaction on May 6, 2026, and the…
• Income Tax Rate ChangesImportance 71 · Surprise 82
  The reported tax rate for the first nine months of 2026 was 4.5%, compared with 17.2% in the same 2025 period; the rate from continuing operations was 17.4% versus 18.1%. A $383 million discrete tax benefit in the…
• Restructuring and Cost SavingsImportance 58 · Surprise 42
  On July 21, 2026, the Board approved and Boston Scientific committed to a new global restructuring program intended to improve cost efficiency and align resources with strategic priorities. The 2026 Restructuring Plan…
• Stock Repurchase ProgramImportance 57 · Surprise 42
  On February 18, 2026, the board added $4.0 billion to the existing $1.0 billion share-repurchase authorization, bringing the total authorization to $5.0 billion. Under an accelerated share repurchase agreement, Boston…
• Cybersecurity Incident DisruptionImportance 53 · Surprise 68
  Boston Scientific identified a cybersecurity incident in August 2026 that disrupted global operations, including manufacturing and the processing and shipment of customer orders. The company said the incident…
• Revenue Performance and MixImportance 43 · Surprise 32
  Net sales increased 1.5% to $5.138 billion in the third quarter of 2026 and 6.7% to $15.784 billion in the first nine months, with nine-month organic growth of 5.8%. Nine-month Cardiovascular sales grew 7.8% to $10.532…
• Net Income and EPS PerformanceImportance 38 · Surprise 30
  Third-quarter reported net income attributable to Boston Scientific common stockholders declined 22.9% year over year, and diluted EPS fell 20.6% to $0.40. Adjusted net income declined 5.5% to $1.063 billion and…
• Gross Margin DriversImportance 33 · Surprise 32
  Third-quarter gross profit was $3.428 billion, down from $3.542 billion a year earlier, and gross margin declined from 69.9% to 66.7%. The 3.2-percentage-point quarterly margin decline included a 1.7-point adverse…
• Products and TechnologyImportance 26 · Surprise 24
  Boston Scientific attributed Cardiovascular growth to its coronary therapies franchise, led by the AGENT Drug-Coated Balloon, and, for the first nine months, to Electrophysiology led by the Farapulse Pulsed Field…
• Competition and Market ShareImportance 26 · Surprise 24
  Boston Scientific reported increased competition in its Electrophysiology business unit during the third quarter and first nine months of 2026. Competition offset growth in Cardiovascular and contributed to pressure on…
• Operating Cash Flow and CapexImportance 25 · Surprise 32
  Operating cash flow was $2.870 billion in the first nine months of 2026, down $301 million from the prior-year period, primarily because of increased working-capital payments. Investing activities used $2.984 billion,…
• China Pricing PressureImportance 20 · Surprise 24
  Volume-based procurement (VBP) in China contributed to third-quarter Endoscopy sales declines. In Urology, VBP-related underperformance in the stone franchise contributed to declines in both the third quarter and first…
• Liquidity and Capital PositionImportance 13 · Surprise 6
  At September 30, 2026, Boston Scientific held $609 million of unrestricted cash and cash equivalents. It had $1.029 billion outstanding under its commercial-paper program, no borrowings under its $3.0 billion revolving…

Revenue by Product (in millions)

Revenue by Geography (in millions)